Specialty Pharmacy

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

The multi-national phase 3 clinical trial on the novel drug as a treatment option for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments.

The National Association of Specialty Pharmacy has named Andy Slavitt, former Center for Medicare and Medicaid Services acting administrator, as the second keynote speaker for their seventh annual meeting.

Pharmacy owners should spend time reviewing marketing arrangements with an attorney who is well-versed in the anti-kickback law to avoid potential pitfalls.

Updated analysis shows favorable survival outcomes with nivolumab and ipilimumab and provides evidence of long-term survival in patients with advanced melanoma.

Top news of the day from across the health care landscape.

Study could lead to advances in HIV vaccine development because functional immunity to HIV is needed from a vaccine.

Researchers studied the quality of life, pain, Global Health Status, and adverse effects.

A study investigates whether a high-dose of vitamin D with or without exercise is a safe, effective option to prevent bone loss.

Expanded Medicare under the Affordable Care Act nearly eliminated racial disparities in access to timely cancer treatment between African American and white patients.

The Affordable Care Act was associated with more diagnoses of early-stage ovarian cancer and more women who received timely treatment.

To elevate the burden on many patients with HER2-positive breast cancer, investigators tested whether a targeted therapy of trastuzumab emtansine plus pertuzumab would lead to a safer option than traditional therapy.

Daily servings of fruits, vegetables, and grains associated with a lower risk of death from breast cancer.

An abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting showed end-of-study analysis results of the phase 3 CLEOPATRA trial.

The study evaluated the activity and tolerability of venetoclax combined with cytarabine or cytarabine/idarubicin in pediatric patients with relapsed/refractory acute myeloid leukemia.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Valoctocogene roxaparvovec (BioMarin) met pre-specified criteria for Factor VIII activity levels treating severe hemophilia A in a phase 3 clinical trial.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

A group of health care providers, including 17 pharmacists, indicated in a recent survey that although they believe that medical marijuana likely provides benefits for patients with cancer, less than half were comfortable recommending its use.

Specialty Pharmacy Times® is on site at the American Society of Clinical Oncology Annual Meeting to provide you with coverage of the conference in real time.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Nearly half of evaluable patients with rare central nervous system tumors, neuroblastoma, or other solid tumors had responses to entrectinib.

Lowest test dose of oxaliplatin and capecitabine was comparable to the highest dose in delaying advanced gastroesophageal cancer progression and minimizing adverse effects.

Lenalidomide found to prevent the formation of blood vessels that feed tumors, yet carries significant adverse effects.

As more novel therapies emerge from the pipeline and enter the market, it is crucial for pharmacists to monitor new drug approvals that could be lifechanging for their patients.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

Top news of the day from across the health care landscape.

A ‘fail-first’ policy by the Centers for Medicare and Medicaid Services could be a nightmare for patients with cancer, according to the Community Oncology Alliance.

The importance of improving the specialty pharmacy experience for patients newly diagnosed with a life-changing disease.